Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Phase 1 Completed 37 enrolled ImmunoVaccine Technologies, Inc. (IMV Inc.)

Non-randomizedSequentialOpen-labelTreatment

Summary

As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or peritoneal cancer.

Timeline

Start: 2013-08-23
Primary completion: 2016-09-08
Completion: 2019-09-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DPX-Survivac(Aqueous)	Vaccine	—	Subcutaneous
Subject	maveropepimut-S	Vaccine	—	Subcutaneous
Background	Cyclophosphamide	Other / unclassified	—	Oral

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Summary

Timeline

Drugs

Indications